^
    5d
    Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration (clinicaltrials.gov)
    P2, N=15, Recruiting, Adverum Biotechnologies, Inc.
    New P2 trial
    6d
    CLTW888A11301: Study of Efficacy and Safety of Voretigene Neparvovec in Japanese Patients With Biallelic RPE65 Mutation-associated Retinal Dystrophy (clinicaltrials.gov)
    P3, N=4, Completed, Novartis Pharmaceuticals | Active, not recruiting --> Completed
    Trial completion
    6d
    RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome) (clinicaltrials.gov)
    P3, N=2, Active, not recruiting, REGENXBIO Inc. | Suspended --> Active, not recruiting
    Enrollment closed
    7d
    Acclaim-2: Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer (clinicaltrials.gov)
    P1, N=5, Terminated, Genprex, Inc. | Phase classification: P1/2 --> P1
    Phase classification
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    ALK mutation
    |
    Keytruda (pembrolizumab) • docetaxel • Cyramza (ramucirumab) • Reqorsa (quaratusugene ozeplasmid)
    7d
    Acclaim-3: Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients (clinicaltrials.gov)
    P1/2, N=62, Recruiting, Genprex, Inc. | Trial primary completion date: Feb 2026 --> Jun 2026
    Trial primary completion date
    |
    Tecentriq (atezolizumab) • Reqorsa (quaratusugene ozeplasmid)
    14d
    SGT-003-301: A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (2025-522949-22-00)
    P2/3, N=20, Not yet recruiting, Solid Biosciences Inc.
    New P2/3 trial
    19d
    ASPIRE: Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome (clinicaltrials.gov)
    P3, N=3, Recruiting, Taysha Gene Therapies, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    19d
    A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED) (clinicaltrials.gov)
    P1/2, N=15, Recruiting, Prevail Therapeutics | Trial completion date: Nov 2031 --> Aug 2032 | Trial primary completion date: Nov 2031 --> Aug 2032
    Trial completion date • Trial primary completion date
    19d
    ARTEMIS: Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration (clinicaltrials.gov)
    P3, N=311, Active, not recruiting, Adverum Biotechnologies, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Eylea (aflibercept intravitreal)
    21d
    NAAVIGATE: Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema (clinicaltrials.gov)
    P2/3, N=576, Recruiting, AbbVie | Not yet recruiting --> Recruiting
    Enrollment open
    22d
    RELIEF: RP-008 in Combination With Daily Oral Varenicline for the Treatment of Trigeminal Neuralgia (clinicaltrials.gov)
    P1/2, N=24, Recruiting, Kriya Therapeutics, Inc.
    New P1/2 trial
    23d
    NAAVIGATE: Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema (clinicaltrials.gov)
    P2/3, N=576, Not yet recruiting, AbbVie
    New P2/3 trial